ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer.

Rodney P RocconiLaura StanberyMin TangAdam WalterBradley J MonkThomas J HerzogRobert L ColemanLuisa ManningGladice WallravenStaci HorvathErnest BognarNeil SenzerScott BrunJohn J Nemunaitis

Published in: Communications medicine (2022)

NSA should be considered for application to investigational targeted therapies in order to identify populations most likely to benefit from treatment, in preparation for efficacy conclusive trials.

Keyphrases

stem cells
clinical trial
randomized controlled trial
combination therapy
smoking cessation
study protocol
phase ii
nk cells
solid phase extraction